Celestial Biolabs (BOM:532871) EBIT : ₹-2.77 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Celestial Biolabs EBIT?

Celestial Biolabs's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was ₹-0.37 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-2.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Celestial Biolabs's annualized ROC % for the quarter that ended in Dec. 2023 was -0.84%. Celestial Biolabs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Celestial Biolabs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.67%.

Celestial Biolabs EBIT Historical Data

The historical data trend for Celestial Biolabs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celestial Biolabs EBIT Chart

Celestial Biolabs Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

Get a 7-Day Free Trial

26.51

-983.18

-1.71

-3.68

-5.73

Celestial Biolabs Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Dec23
EBIT	Get a 7-Day Free Trial															-0.55	-0.81	-1.52	-2.39	-0.37

Competitive Comparison of Celestial Biolabs's EBIT

For the Biotechnology subindustry, Celestial Biolabs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celestial Biolabs's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celestial Biolabs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Celestial Biolabs's EV-to-EBIT falls into.

Celestial Biolabs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2.77 Mil.

Celestial Biolabs (BOM:532871) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Celestial Biolabs's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-1.492 * ( 1 - 0% )	/	( (177.879	+	0)	/ 1 )
=	-1.492	/	177.879
=	-0.84 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	172.367	-	5.971	-	( 0.233	-	max(0, 54.884	-	43.401	+	0.233	))
=	177.879

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Celestial Biolabs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.492	/	( ( (129.61 + max(18.817, 0))	+	(0 + max(0, 0)) )	/	1 )
=	-1.492	/	( ( 148.427	+	0 )	/	1 )
=	-1.492	/	148.427
=	-1.01 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(37.076	+	0.338	+	5.754)	-	(5.971	+	0	+	18.38)
=	18.817

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Celestial Biolabs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-2.766	/	165.669
	=	-1.67 %

Celestial Biolabs EBIT Related Terms

Thank you for viewing the detailed overview of Celestial Biolabs's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Celestial Biolabs (BOM:532871) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celestial Biolabs Ltd (BOM:532871) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Plot No. 59, Road No 12, TSIIC Tech Park, IDA Nacharam, Hyderabad, TG, IND, 500076

Website

http://www.celestialbiolabs.com

Celestial Biolabs Ltd is an India based biopharmaceutical company. It is engaged in the business activity producing and supplying of the biotechnological products. The company offers herbal, feed supplement and nutraceutical products. The proprietary herbal products of the group include BIOVITA, CADALMIN GAE, CEL-DIGEST, BIOLIV, RHUMACEL, CEL-CLEAR, Trem Plus, O-KOF, BIOPOWER GOLD, BIO-DNORM, DERMACEL, GYNOCEL, HEALTHONE, RELIFIN, and C-KAPS. The organization formulates and manufactures Ayurvedic proprietary products for the Indian market.

Celestial Biolabs (BOM:532871) Headlines

No Headlines